Clonal hematopoiesis can develop from JAK2 V617F mutant cells, but mouse models harboring this mutation are confounded by myeloproliferative disease phenotypes.
C lonal hematopoiesis of indeterminate potential (CHIP) or age-related clonal hematopoiesis (ARCH) is a prevalent condition in elderly individuals in which a substantial portion of mature blood cells are derived from a single dominant hematopoietic stem cell (HSC) clone (1) (2) (3) . In a portion of individuals, this clonal hematopoiesis event can be attributed to mutations in "driver" genes that are recurrently mutated in hematologic malignancies.
These mutated genes include DNMT3A, TET2, ASXL1, and others. These mutations are thought to provide the HSC with a competitive advantage such that it undergoes clonal amplification and gives rise to differentiated blood cell progeny that also harbor pre-leukemic mutations. Notably, the mutations that give rise to clonal hematopoiesis do not overtly alter blood cell counts or give rise to other features of hematologic malignancy. The existence of clonal hematopoiesis has been known for decades (4, 5) , but it had generally been viewed as a benign condition and that it might provide a counterbalance to HSC exhaustion that occurs in elderly individuals (6) . However, recent epidemiological studies have shown that clonal hematopoiesis is associated with an appreciable increase in mortality in the general population as well as in patient cohorts (7) (8) (9) (10) (11) (12) . In some instances, clonal hematopoiesis has been associated with an increased risk of cardiovascular disease, including coronary artery disease, ischemic stroke, and early onset myocardial infarction (10, 13) . Studies in experimental models have provided evidence that inactivating mutations in TET2
can causally contribute to atherosclerosis and heart failure through an interleukin (IL)-1 beta-dependent mechanism (14, 15) .
Similarly, experimental studies have shown that mutations in DNMT3A can contribute to myocardial inflammation and heart failure (16) . Recently, hematopoietic mutations in TET2 and DNMT3A have been associated with the progression and poor prognosis in patients with chronic ischemic heart failure (17) . Because it has been reported that inflammation favors the expansion of JAK2 V617F cells relative to wild-type cells (38, 39) , we tested whether the sys- Figure 5 ). This manipulation led to reductions in STAT1 phosphorylation in the Jak2 V617F -expressing cells ( Figure 2C) .
These results indicate that Jak2 V617F requires IFNGR1
for downstream signal transduction in THP-1 cells. In contrast, similar manipulations targeting other cytokine receptors, including the interferon lambda receptor, the erythropoietin receptor, or the granulocyte colony-stimulating factor receptor, did not affect JAK2 V617F -STAT1 signaling (data not shown). Figure 4A) . Notably, these mice did not display cardiac hypertrophy in the absence of surgical cardiac injury ( Figure 4C ). This finding is in contrast to competitive BMT experiments employing bone marrow from mice that express Jak2 V617F under the vav1 promoter (Supplemental Figure 2 ), suggesting that cardiac hypertrophy in the absence of surgical cardiac injury is secondary to conditions associated with MPN phenotype and not a feature of myeloid restricted Jak2 V617F expression.
Upon stimulation with LPS, cells transduced with
In response to pressure overload hypertrophy, the JAK2 V617F experimental group displayed significant increases in heart mass (p < 0.001) and lung weight (p < 0.001) indicative of congestion compared with mice from the JAK2 WT experimental group at 8 weeks post-surgery ( Figure 4B) . Sequential analysis of echocardiography revealed that the JAK2 V617F experimental group displayed significantly increased cardiac posterior wall thickness (Sidak's 95% confidence interval: -0.19 to -0.07; p < 0.001) and a progressive reduction of fractional shortening (Sidak's 95% confidence interval: 9.30 to 14.73; p < 0.001) ( Figure 4C) .
Correspondingly, histological analyses revealed that the TAC-treated JAK2 V617F group displayed more cardiac myocyte hypertrophy (p < 0.001) ( Figure 4D) and cardiac fibrosis (p < 0.001) ( Figure 4E 
DISCUSSION
Myeloproliferative neoplasms are rare blood disorders that are frequently associated with somatic JAK2 V617F mutation in hematopoietic cells. These conditions lead to elevations in erythrocytes and platelets that have the potential to contribute to cardiovascular disease through increased blood viscosity and thrombotic complications (18, 19, 46) .
Additionally, these conditions are associated with leukocytosis that can also contribute to cardiovascular diseases (47) (48) (49) . Recently, it has been recognized that asymptomatic adults display clonal events in their hematopoietic system that result from JAK2 V617F
mutations, yet they do not display overt changes in leukocytes, erythrocytes, or platelets. This condition, referred to as clonal hematopoiesis (or CHIP or ARCH), is prevalent in the elderly population and has been associated with increased mortality and cardiovascular disease incidence (13) . Clonal hematopoiesis associated with candidate genes that are recurrently mutated in hematologic malignancies is estimated to occur in 10% of individuals who are older than 70 years of age. Of these, the activating JAK2 V617F mutation can account for a portion of the reported cases of clonal hematopoiesis cases, yet these individuals do not display abnormalities in total blood counts (10, 13) . Thus, the mechanisms leading to the increased cardiovascular disease incidence caused by JAK2 V617F -mediated clonal hematopoiesis are enigmatic.
Here, we evaluated the fitness of HSCs expressing a JAK2 V617F transgene to repopulate bone marrow in lethally irradiated mice using a competitive transplantation approach. Analysis of the blood of transplanted mice established that this BMT led to the preferential expansion of mutant JAK2 hematopoietic cells to an extent that was comparable to the allelic fractions that are observed in individuals with clonal hematopoiesis (8, 10, 13) . The kinetics of this expansion was similar to that previously observed in competitive transplantation experiments using bone marrow harboring inactivating mutations in Tet2 but much more robust than what was observed with inactivating mutations in Dnmt3a (14-16), indicative of gene-specific effects of these mutations in the HSPC compartment. A particularly striking observation was that while the Tet2 and Dnmt3a mutations in HSPCs tended to be multipotent and represented in all progeny leukocytes, BMT experiments with the JAK2 V617F mutation displayed a nearly exclusive bias toward expansion into neutrophils and monocytes versus the lymphoid lineage. Consistent with these findings, a model of Jak2 V617F knock-in mice also display a myeloid bias of cell expansion (50, 51) . We and others also find that the JAK2 V617F mutation promotes the expression of CD41 in the LT-HSC population, a marker that is expressed on a subpopulation of myeloid-biased HSC that accumulate with age (36) . Along these lines, lineagerestricted expansion is generally observed in patients with clonal hematopoiesis, typically with much higher mutant allele fractions in the myeloid population (52, 53) .
Although mice transplanted with JAK2 V617F bone marrow developed a strong expansion bias into myeloid cell populations, they also developed elevations in hemoglobin, platelets, and leukocytes that are associated with MPNs. These phenotypes are also observed in murine models of hematopoietic cell-specific Jak2 V617F expression (28) (29) (30) (31) . However, alterations in blood cell counts are generally not a feature of the clonal hematopoiesis that can arise from mutations in any 1 of multiple pre-leukemic genes including the Jak2 V617F variant. To account for these discrepant phenotypes between JAK2 V617Fmediated MPNs and clonal hematopoiesis, it has been proposed that heterogeneity among the HSC populations that acquire the JAK2 V617F mutation may contribute to the phenotypic diversity observed in this patient population (54) . It is becoming increasingly recognized that distinct HSC subpopulations differ in their functional properties and display restricted lineage biases (55) (56) (57) (58) (59) . Thus, it has been proposed that essential thrombocytopenia can result from a JAK2 V617F mutation that is acquired in megakaryocyte-restricted HSCs, whereas polycythemia vera can result when the mutation is acquired in HSCs that are destined for myeloid-or erythroid-restricted progeny (54) . Support for these more complex lineage schemes comes from evidence of bypass pathways involving lineage-restricted progenitors that are self-renewing (56, 57) , and longlived, lineage-biased HSCs that predominate in native hematopoiesis (58, 60) . Alternatively, it remains possible that clonal hematopoiesis and the diverse MPN disease phenotypes could result from the length of time that a patient harbors the mutation, the size of the clone, or the acquisition of additional driver gene mutations (61, 62) .
Previous studies have implicated JAK2 V617Fmediated clonal hematopoiesis without an MPN disease phenotype in cardiovascular disease (13) . To model the effect of myeloid-restricted JAK2 V617F expression on the cardiovascular system, BMT experiments were conducted using lineage-negative cells that were transduced with a lentivirus vector expressing JAK2 V617F from the SP146/gp91 promoter/ enhancer. This synthetic promoter/enhancer is active in myeloid cells of the blood and tissues (33, 41) , and it is more tissue restricted in this context than the LyzM promoter that is active in HSPCs in this context (30). Based on these results, we hypothesize that clonal hematopoiesis that results in the expression of the JAK2 V617F mutation in circulating myeloid cells can contribute to myocardial disease independent of thrombocytosis, erythrocytosis or leukocytosis.
It is increasingly appreciated that inflammation plays a causal role in cardiovascular diseases (63) (64) (65) (66) .
Here, we find that myeloid-directed JAK2 V617F expression can increase myocardial inflammation in murine models of heart failure and increase inflam- binding to a cytokine receptor scaffold is still required for JAK2 V617F to transmit a signal (40) . While the receptors involved in JAK2 V617F activation have been reported in several cell types, the receptors that confer this function in myeloid cells have not been elucidated. In the current study, we find that IFNGR1
is necessary for JAK2 V617F to activate phosphorylated A recent publication showed that JAK2 V617F mutant neutrophils are prone to form neutrophil extracellular traps (NETs) and contribute to the thrombotic events that accompany myeloproliferative disease (68).
NETs have been reported to promote cardiac dysfunction in the context of myocardial ischemia (69) and pressure overload (70) . Thus, the formation of NETs could be another mechanism that can contribute to the cardiovascular consequences of the JAK2 V617F mutation. However, JAK2 has cell typespecific functions, as it functions downstream of multiple receptors in different cell types to differentially activate specific downstream signaling pathways and produce different outcomes. Thus, in the current study, we focused on analyzing JAK2 V617F mutations in the monocyte or macrophage population because they are widely recognized to be critical cells in cardiovascular disease models (64) . 
CONCLUSIONS
We show that JAK2 V617F expression in HSPCs leads to the expansion of the mutant clones in a manner that is highly restricted to myeloid cells. This expression pattern differs markedly from HSPC that harbor mutations in Tet2 or Dnmt3a, which display the ability to expand into all leukocyte populations in the competitive BMT model (14-16). Further, we developed a system to restrict JAK2 V617F expression to differentiated blood myeloid cells following transduction of lineage-negative bone marrow cells that were implanted into lethally irradiated mice. Mice treated in this manner did not display alterations in blood cell or platelet levels, but they were more susceptible to myocardial inflammation and cardiac dysfunction in models of heart failure. We propose that JAK2 V617F mutations can occur in a clonal subpopulation of HSC that exclusively gives rise to circulating myeloid cells that, in turn, contribute to cardiovascular disease risk through the overactivation of cytokine pathways. Thus, patients with JAK2 V617F -mediated clonal hematopoiesis may benefit form therapies that target pathways activated by this mutant kinase. 
